Home / Research / Cardio on GLP-1s

Evidence teardown · randomized exercise and GLP-1 trials, the Zepbound label, ClinicalTrials.gov review · Sources checked October 19, 2026

Is cardio a waste of time unless you’re on Zepbound or Wegovy? Exercise still works without the drug, and on one it added fat loss. Nobody has tested cardio with tirzepatide.

A fitness influencer’s post says cardio is “an utter waste of time unless you are on Tirzepatide,” because extra hunger cancels the calories you burn.[1] The trials say that’s half right. People do eat back part of what they burn, but only part. Exercise alone still took off weight in a 10-month trial, and in a year-long trial it kept 4.1 kg off after a diet without making people hungrier.[7][8][3][4] When that same trial added exercise to a GLP-1 drug, body fat fell about twice as much as with either one alone, and a year after everyone stopped, the exercise benefit had held up better than the drug’s.[3][5] But the drug was liraglutide (Saxenda), not tirzepatide (Zepbound). Of 11 registered trials that give semaglutide or tirzepatide with and without an exercise program, 0 have results, and the only tirzepatide one that includes cardio hasn’t started.[12]

Why this matters this week

On Sunday afternoon, October 18, the fitness creator Greg O’Gallagher posted that “cardio for fat loss is an utter waste of time unless you are on Tirzepatide,” since “any calories you burn through effort will be off set by the proportionate increase in hunger,” while “on tirzepatide appetite stays dialled.” By midnight it had about 31,000 views.[1] The bodybuilder Marc Lobliner answered that “Cardio + Diet has helped many folks lose weight at all levels long before GLP-1,” and X ran a trending story on the argument.[2] It’s a question a lot of people on these drugs actually face: is the treadmill worth it? It also has a testable core, so we checked it.

The short answer

Exercise without the drug isn’t a waste. It loses less weight than the calorie math predicts, because people eat a bit more, but it still loses weight and helps keep it off.[7][8][3] With a GLP-1 drug, adding exercise did add fat loss in the one solid trial of the combination.[3] So the second half of the claim has some support, for an older drug. For tirzepatide specifically, it has never been tested.[12] And the Zepbound label already says to use the drug with “increased physical activity.”[9]

Claim 1: “Calories you burn will be offset by the increase in hunger”

This is a real effect, called compensation, and it’s been measured carefully. In the E-MECHANIC trial, 198 adults with overweight or obesity did supervised exercise for 24 weeks at one of two doses. Using a gold-standard method (doubly labeled water), researchers found people ate about 91 to 124 more calories a day. They ended up 1.5 to 2.7 kg short of the weight loss their workouts should have produced.[8] Their metabolism and everyday movement didn’t change. The extra eating explained it.[8]

But compensation is partial, not “proportionate.” In Midwest Exercise Trial 2, 141 sedentary young adults with overweight or obesity did supervised cardio five days a week for 10 months, burning 400 or 600 calories a session, with no diet. Those who completed at least 90% of sessions lost 3.9 kg (4.3%) and 5.2 kg (5.7%). The control group gained 0.5 kg.[7] That’s modest next to tirzepatide’s 15–21% in SURMOUNT-1, but it isn’t zero.[10]

And in the trial that tested exercise right after weight loss, when hunger usually climbs, exercise didn’t raise appetite compared with placebo, even though people were burning more.[4] One year of exercise also raised the body’s own late after-meal GLP-1 response by 37% within that group, a 25% bigger rise than in people with usual activity. The drug groups saw no such change.[6]

Claim 2: “On tirzepatide, burning more calories results in greater fat loss”

The best test of this idea is S-LiTE, a Danish trial published in NEJM in 2021. 195 adults with obesity first lost an average of 13.1 kg on an 8-week low-calorie diet. Then they were randomly assigned for a year to a vigorous exercise program (indoor cycling and circuit training twice a week, supervised, plus two sessions on their own), the GLP-1 drug liraglutide 3.0 mg a day, both, or placebo.[3][5]

Compared with placebo, exercise kept off 4.1 kg more, liraglutide 6.8 kg more, and the combination 9.5 kg more. Body-fat percentage fell 3.9 points with the combination, about twice as much as with exercise (1.7) or liraglutide (1.9) alone.[3] Only the combination improved blood sugar (HbA1c), insulin sensitivity and fitness.[3] So on a GLP-1, exercise did add fat loss. One detail cuts the other way: on body weight, the combination beat liraglutide alone by 2.7 kg, a gap small enough that it could have been chance (P = 0.13).[3]

The part missing from the X argument is what happened after. A year after all treatment ended, 109 of the participants came back. People who had been on liraglutide alone had regained 9.6 kg. The exercise group had regained 3.6 kg, and the combination group 7.1 kg.[5] The exercisers were also still moving: a median of 240 minutes a week, against 30 minutes for people who’d had liraglutide alone.[5] Only two-thirds of finishers came back, and these follow-up differences didn’t pass the study’s own strict test for multiple comparisons, so treat them as a strong hint rather than proof.[5]

What’s missing: tirzepatide

Liraglutide is an older, daily GLP-1 drug. In a head-to-head trial, people lost 6.4% of their weight on it against 15.8% on semaglutide (Wegovy).[13] The claim is about tirzepatide, so we looked for trials that test it, or semaglutide, with and without exercise.[12]

We pulled all 1,006 semaglutide and tirzepatide studies on ClinicalTrials.gov and read every one whose interventions mention exercise. 11 are randomized trials that give the drug with a structured exercise program in one group and without it in another. 5 of them test only weight training, mostly to see whether it protects muscle. 4 include cardio, and 2 don’t say what kind of exercise. None has posted results.[12]

The only tirzepatide trial that says it includes cardio is a University of Virginia study of 24 people over 16 weeks, with weight as its main outcome. It hasn’t started recruiting.[12] The oldest trial on the list, a 30-person Copenhagen study of semaglutide with or without cycling that began in 2019, has an unknown status and no posted results.[12]

What the big drug trials already assumed

Every headline number for these drugs came with exercise advice. In SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide), everyone, placebo included, got regular counseling to cut 500 calories a day and get at least 150 minutes of activity a week.[10][11] Zepbound’s label says it’s for use “in combination with a reduced-calorie diet and increased physical activity.”[9] The trials didn’t measure how much people actually exercised, so they can’t say how much of the result the activity advice explains.[10][11]

Safety

Two label warnings matter for anyone adding hard cardio on Zepbound. First, the drug can cause acute kidney injury from dehydration, usually in people with nausea, vomiting or diarrhea, and the label tells patients “to take precautions to avoid fluid depletion.” The label says to watch for this especially while the dose is being started or raised, so that’s a time to be careful about fluids on long, sweaty sessions.[9] Second, low blood sugar: in a type 2 diabetes trial, 10.3% of people taking Zepbound with a sulfonylurea had hypoglycemia, against 2.1% without one, and it has also been reported in people without diabetes. The label says to consider lowering insulin or sulfonylurea doses when starting Zepbound, so anyone on those drugs should ask their prescriber before adding hard exercise too.[9] In S-LiTE, raised heart rate and gallstones were more common on liraglutide alone than on liraglutide plus exercise.[3]

What holds up

S-LiTE is a randomized, placebo-controlled, double-blind trial (for the drug), with supervised exercise checked by heart-rate monitors and DEXA scans for body fat.[3][5] E-MECHANIC and Midwest Exercise Trial 2 used supervised, measured exercise, not self-report.[7][8] The limits: S-LiTE used liraglutide, tested weight maintenance after a diet rather than initial loss, and was funded partly by the Novo Nordisk Foundation, with several authors reporting Novo Nordisk ties.[3][5] Midwest Exercise Trial 2 counted only people who did at least 90% of sessions, and its participants averaged 22 years old.[7]

Bottom line

Is cardio pointless unless you’re on Zepbound? No. Hunger eats back part of what exercise burns, not all of it, and exercise helped people keep weight off after a diet without raising their appetite.[4][7][8] On a GLP-1 drug, exercise roughly doubled the drop in body fat in the one strong trial, and its benefit lasted better than the drug’s once treatment stopped.[3][5] Whether the same holds for tirzepatide is a fair guess that nobody has tested yet: 0 of 11 registered trials have results.[12]

This page analyzes published trials, a drug label and trial registry records. It is not medical advice. Talk to your prescriber before starting a hard exercise program on a GLP-1 medicine, especially if you take insulin or a sulfonylurea. The trial-registry review is Jabbit’s own; inputs are cited above.